Promising Pathways for Blood Biomarkers: Breaking Down Bio-Hermes Study

Life Sciences, Clinical Trials, Drug Discovery & Development, Biomarkers,
  • Tuesday, June 04, 2024

Discover an informative webinar elaborating on the first results from the Bio-Hermes-001 Study. This study compared the results of digital and blood biomarkers with brain amyloid positron emission tomography (PET) scans or cerebrospinal fluid assays and revealed a strong correlation between several blood tests, particularly p-tau 217, with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer’s disease.

In this webinar, experts in the field will elaborate upon blood biomarkers and the findings of the Bio-Hermes-001 study, as well as how they will enhance the field’s ability to provide a more economical, timely and accurate diagnosis of Alzheimer’s disease and improve enrolment into clinical trials. Additionally, the speakers will provide an overview of the Bio-Hermes biomarker data challenge during this important discussion.

The attendees will also get to learn about the study’s methodology, initial outcomes and the future implications for Alzheimer’s diagnostics and research.

Register for this webinar today to understand how the correlation between digital and blood biomarkers with the presence of beta-amyloid in the brain could transform Alzheimer’s diagnostics.


Phyllis Barman Ferrell, Alzheimer’s and Brain Health

Phyllis Barkman Ferrell, DrPH, MBA, Independent Advisor – Alzheimer’s and Brain Health

Phyllis Barkman Ferrell is an innovator, investor and incubator for brain health and longevity. After three decades as a life sciences executive at Eli Lilly & Company, Phyllis retired from the pharmaceutical business and is now working as an independent advisor for multiple clients and is the Chief Impact Officer for the health start-up Alzheimer’s Moonshot, a new global initiative that aims to break down silos and foster meaningful collaboration and entrepreneurial support between mission-aligned founders and champions.

At Lilly, Phyllis held many leadership roles throughout the organization. In 2011, Phyllis took on the leadership role for the late-stage Alzheimer’s therapeutic and diagnosis assets in Lilly’s pipeline. Since that moment, she has been a relentless advocate for the patients living with the disease and those that love them.


In 2020, Phyllis was placed as an executive-on-loan to the World Economic Forum-commissioned Davos Alzheimer’s Collaborative (DAC), where she has served as the visionary and founder of the Healthcare System Preparedness program. DAC is a global multi-stakeholder partnership of organizations aimed at mobilizing the world against Alzheimer’s disease, with the specific focus of ensuring that health systems are prepared to embrace innovation and better care for our global aging population.

Phyllis has a BA in Economics from DePauw University, an MBA from Stanford University and a PhD in Global Public Health Leadership from Indiana University. Phyllis is a current member of the World Dementia Council and serves on many boards and advisory committees in the field. Phyllis is passionate about Alzheimer’s advocacy and brain health so that other boys do not have to grow up without their grandfathers’ presence as her sons did.

Read Less...

Message Presenter
Nicholas Ashton, University of Gothenburg

Nicholas Ashton, Senior Director, Biomarker Program; Associate Professor, University of Gothenburg

After receiving his PhD from King’s College London under the mentorship of Simon Lovestone, Dr. Nicholas Ashton joined the laboratory of Drs. Henrik Zetterberg and Kaj Blennow at the University of Gothenburg, Sweden, where he has made major contributions to the development and use of biofluid assays for Alzheimer’s disease and related disorders.

Several of the assays that he has developed and tested are widely used in the research setting and are being refined for use in the clinical setting. Over the last decade, he published more than 200 original research articles and received the Queen of Sweden Prize to a Young Alzheimer’s Research and the Viola Bergvist award for mentorship.


He is commonly lauded for his leadership skills and working relationships, internationally recognized for his contributions to the field and at the age of 36 was on Clarivate’s list of the world’s most highly cited researchers. Dr. Ashton leads harmonization efforts for fluid biomarkers for the Alzheimer’s Association and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to achieve biomarker-common results across the globe.

Dr. Ashton’s recent appointment as the Senior Director of the Banner Health Biomarker Program includes two new state-of-the-art laboratories on the BSHRI campus. His Biomarker Discovery Laboratory will develop, optimize and validate new spinal fluid and blood tests for Alzheimer’s disease and other neurodegenerative and cerebrovascular diseases. The tests include remote blood tests that can be administered at home, setting the stage for their widespread use in research studies, treatment and prevention trials, and their use in the clinical setting.

His Biomarker Assessment Laboratory will provide a state-of-the-art resource for the performance of rapid, rigorous and high-throughput resource biological fluid assays for academic and industry researchers to advance the scientific understanding, treatment and prevention of neurodegenerative and cerebrovascular diseases and leverage the latest immuno- and mass spectroscopy platforms, reagents and methods.

Read Less...

Message Presenter
Laura Nisenbaum, Alzheimer’s Drug Discovery Foundation

Laura Nisenbaum, PhD, Executive Director of Drug Development, Alzheimer’s Drug Discovery Foundation

Dr. Laura Nisenbaum is a proven scientific leader with 30 years of biotechnology industry and academia experience. At the ADDF, she oversees the Scientific Affairs, Biomarker Development and Aging and Alzheimer’s Prevention teams.

Most recently, Dr. Nisenbaum served as Senior Director of Aducanumab Biomarkers and Diagnostic Pathways at Biogen, where she led the biomarker strategy for Aducanumab and the Diagnostics Pathway group within the biomarker organization.


Her time at Biogen followed 20 years of experience at Eli Lilly and Company where she served as Asset Manager for Chorus, an autonomous early-phase clinical development organization within Lilly. Dr. Nisenbaum also served as a Research Fellow and neuroscience lead in tailored therapeutics, translational medicine and preclinical drug discovery. Prior to joining the biotechnology field, Dr. Nisenbaum received a Fulbright Scholarship to study in Cologne, Germany. She then completed her PhD in Neuroscience in 1991 at the University of Pittsburgh and transitioned to industry after completing postdoctoral training at the National Institutes of Health (NIH), the University of Tennessee College of Medicine and a faculty position in Physiology and Neurobiology at the University of Connecticut.

Throughout her career, Dr. Nisenbaum has contributed to the discovery and development of more than 15 novel therapeutics, bringing three molecules for FDA approval. She has also authored over 35 publications in peer-reviewed scientific journals.

Read Less...

Message Presenter

Who Should Attend?

This webinar will appeal to:

  • Alzheimer’s researchers
  • Alzheimer’s drug development leadership

What You Will Learn

Attendees will learn about:

  • The Bio-Hermes-001 study and initial findings
  • Using the findings from the Bio-Hermes-001 study to improve Alzheimer’s diagnoses and clinical trial enrollment
  • The Bio-Hermes biomarker data challenge

Xtalks Partner

Global Alzheimer’s Platform Foundation (GAP)

The Global Alzheimer’s Platform Foundation (GAP) is a patient-centric, non-profit organization dedicated to speeding the delivery of innovative therapies to those living with Alzheimer’s and Parkinson’s by reducing the time and cost of Alzheimer’s disease (AD) and Parkinson’s disease (PD) clinical trials.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account